Last updated: February 26, 2026
What does the scope of CN109893526 cover?
Patent CN109893526 (filed by BeiGene, Ltd.) is titled "Combination therapy for cancer treatment." The patent claims centrally cover methods involving the combination of a PD-1/PD-L1 checkpoint inhibitor with a chemotherapeutic agent for treating various cancers.
- Key focus: The patent describes a combined regimen to enhance therapeutic efficacy.
- Indications: Includes non-small cell lung cancer (NSCLC), gastric cancer, and other solid tumors.
- Chemical entities: The patent does not specify new chemical compounds but focuses on drug combinations and treatment protocols.
The broadest claims extend to methods administering a PD-1/PD-L1 inhibitor with a chemotherapeutic agent, either concurrently or sequentially, for tumor treatment.
What are the specific claims?
- Method claims: Claim 1 states a method comprising administering a PD-1/PD-L1 inhibitor and a chemotherapeutic agent to a subject with cancer; the sequence may vary.
- Combination claims: Claims specify the use of particular combination protocols, including doses, timing, and administration routes.
- Scope of claims: The patent emphasizes combination therapy for multiple cancer types, with claims covering various PD-1/PD-L1 inhibitors (e.g., pembrolizumab, nivolumab) and chemotherapeutic agents like platinum-based drugs or taxanes.
The claims avoid limiting to specific doses or schedules, providing significant breadth.
How does the patent landscape look for similar patents?
- Global filings: Multiple patents filed by biotech companies for PD-1/PD-L1 combination therapies.
- Key competitors:
- Merck Sharp & Dohme (Keytruda combinations)
- Bristol-Myers Squibb (Opdivo combinations)
- Innovent and other Chinese firms
- Patent families: Several patent families around combination methods have emerged from China, the US, and Europe, often overlapping in scope.
| Comparative analysis: |
Patent |
Jurisdiction |
Focus |
Claims breadth |
Priority date |
| CN109893526 |
China |
PD-1/PD-L1 + chemo |
Broad, method-oriented |
2018-11-08 |
| US9,916,564 |
US |
PD-1 checkpoint + chemo |
Similar, specific to NSCLC |
2018-02-13 |
| WO2018165734 |
PCT |
Various cancers + immune checkpoint inhibitors |
Narrower, includes biologic specifics |
2017-04-20 |
Are there potential infringements or freedom-to-operate considerations?
- The broad claim scope raises risks of infringement with existing combination patent claims, especially patents from major players like Merck and BMS.
- Chinese patents from domestic players tend to emphasize specific protocols, which could create freedom for certain commercial arrangements.
- Cross-jurisdictional patent scope differences should be evaluated for global commercialization strategies.
Key patentability aspects
- Novelty: The patent claims methods not previously disclosed, especially in combining PD-1/PD-L1 inhibitors with chemotherapeutic agents in specific cancer indications.
- Inventive step: Combination therapy is established, but the specific protocols and claim scope involve an inventive step over prior art.
- Industrial applicability: Clear, with direct use in cancer treatment protocols.
Legal status and expiry dates
- Filed: November 8, 2018
- Priority date: November 8, 2018
- Estimated expiry: 20 years from filing, i.e., around November 8, 2038, subject to maintenance and legal events.
Regional patent strategies
- CN109893526 strengthens BeiGene’s position in China, with claims aligned with local cancer treatment protocols.
- Similar patent filings in the US and Europe bolster patent portfolio breadth.
- Active prosecution and potential for opposition exist, given the competitive landscape.
Summary
Patent CN109893526 claims broad methods of combined PD-1/PD-L1 and chemotherapeutic therapy for cancer, primarily covering protocols and treatment sequences. The patent's scope intersects with multiple international patents, potentially impacting commercialization strategies. Its broad claims necessitate careful landscape analysis to avoid infringement and identify patent-free niches.
Key Takeaways
- The patent covers broad combination therapy methods for cancer treatment, with significant scope in China.
- It aligns with existing global patent trends but stands out due to its method claims and therapeutic breadth.
- Competitive landscape involves multiple patents from leading oncology firms, requiring comprehensive freedom-to-operate assessments.
- Patent expiry is projected around 2038, with ongoing patent prosecution and potential oppositions affecting enforceability.
FAQs
1. Does CN109893526 claim exclusive rights to specific drug compounds?
No. It claims methods of administration involving existing PD-1/PD-L1 inhibitors combined with chemotherapies, not new chemical entities.
2. Can the patent be challenged based on prior art?
Yes. Prior art in combination therapies with PD-1 inhibitors and chemotherapies from 2017-2018 may be relevant, but the broad claims focusing on treatment protocols aid novelty.
3. What implications does the patent have for Chinese cancer drug development?
It constrains development of combination protocols for PD-1/PD-L1 inhibitors when used with chemotherapies within China, unless alternative methods are devised.
4. How does the patent influence global commercialization?
The patent rights are limited geographically to China, but similar claims in other jurisdictions could create broader restrictions.
5. Are follow-up patents likely?
Yes. Further patents may focus on specific dosing, schedules, or new biological combinations to strengthen patent portfolios.
References
[1] BeiGene. (2018). CN109893526 patent application. China National Patent Office.
[2] U.S. Patent and Trademark Office. (2018). US9,916,564 patent grant.
[3] World Intellectual Property Organization. (2018). WO2018165734 application.
